Skip to main content

Table 3 Clinical results: multivariate analysis-dependent variable Cancer-Specific Survival at 1 year

From: Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment

ALL PATIENTS: 60

INDEPENDENT VARIABLES:

COEFFICIENT

STD. ERROR

p-value

(Constant)

1575

 

univariate

multivariate

AGE

−0,002

−0,062

0.080

0,654

SEX

0,011

0,013

0.070

0,923

PERFORMANCE STATUS

0,052

0,063

0.078

0,649

HISTOLOGY

−0,095

−0,143

0.340

0,305

STAGE

−0,049

−0,059

0.247

0,671

TREATED BULKY SITE

−0,011

−0,013

0.380

0,921

UNRESCTABLE BULKY NSCLC TUMOR DIAMETER

−0,013

-0,076

0.047

0,584

TREATMENT

-0,353

-0,546

0.049

< 0,0001

  1. Abbreviations: SBRT-PATHY- SBRT PArtial Tumor irradiation of the HYpoxic segment, CHT-chemotherapy, RT- radiotherapy, CR- complete response, PR- partial response, AE- abscopal effect